These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32236408)

  • 1. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
    Shields RK; Iovleva A; Kline EG; Kawai A; McElheny CL; Doi Y
    Clin Infect Dis; 2020 Dec; 71(10):2713-2716. PubMed ID: 32236408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in
    Kawai A; McElheny CL; Iovleva A; Kline EG; Sluis-Cremer N; Shields RK; Doi Y
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms.
    Castanheira M; Lindley J; Doyle TB; Davis AP; Sader HS
    Int J Antimicrob Agents; 2023 Jan; 61(1):106698. PubMed ID: 36464152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.
    Kawai A; Shropshire WC; Suzuki M; Borjan J; Aitken SL; Bachman WC; McElheny CL; Bhatti MM; Shields RK; Shelburne SA; Doi Y
    mBio; 2024 Feb; 15(2):e0287423. PubMed ID: 38179965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
    Di Pilato V; Codda G; Niccolai C; Willison E; Wong JLC; Coppo E; Frankel G; Marchese A; Rossolini GM
    Int J Antimicrob Agents; 2024 Jan; 63(1):107030. PubMed ID: 37931849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of β-lactamase-mediated cefiderocol resistance.
    Fröhlich C; Sørum V; Tokuriki N; Johnsen PJ; Samuelsen Ø
    J Antimicrob Chemother; 2022 Aug; 77(9):2429-2436. PubMed ID: 35815680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
    Le Terrier C; Nordmann P; Buchs C; Poirel L
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
    Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
    Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including
    Gomis-Font MA; Clari MA; López-Causapé C; Navarro D; Oliver A
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0119223. PubMed ID: 38063398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.
    Barnaud G; Labia R; Raskine L; Sanson-Le Pors MJ; Philippon A; Arlet G
    FEMS Microbiol Lett; 2001 Feb; 195(2):185-90. PubMed ID: 11179650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
    Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
    J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019.
    Jean SS; Lee YL; Hsu CW; Hsueh PR
    Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam Resistance Mediated by the N
    Compain F; Debray A; Adjadj P; Dorchêne D; Arthur M
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.
    Lahiri SD; Giacobbe RA; Johnstone MR; Alm RA
    J Antimicrob Chemother; 2014 Nov; 69(11):2942-6. PubMed ID: 24986496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.